RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Innovation Pharmaceuticals Stock

Innovation Pharmaceuticals Stocks 2024

Innovation Pharmaceuticals Stocks

505.77 M

Ticker

IPIX

ISIN

US45782D1000

WKN

A2DTBJ

In 2024, Innovation Pharmaceuticals had 505.77 M outstanding stocks, a 0.38% change from the 503.87 M stocks in the previous year.

The Innovation Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2023505.77
2022503.87
2021386.16
2020237.3
2019178.23
2018144.51
2017127.29
2016119.91
2015115.09
2014105.04
201394.98
201290.16
201190.3
201091.86
200991.84
200852.37
20079.73
20069.33

Innovation Pharmaceuticals shares outstanding

The number of shares was Innovation Pharmaceuticals in 2023 — This indicates how many shares 505.768 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Innovation Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Innovation Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Innovation Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Innovation Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Innovation Pharmaceuticals Aktienanalyse

What does Innovation Pharmaceuticals do?

Innovation Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of novel therapeutics in various areas of medicine. Founded in 2007 as Cellceutix Corporation, the company was renamed Innovation Pharmaceuticals Inc. in 2016. The goal of Innovation Pharmaceuticals is to meet the needs of patients suffering from rare or severe diseases by developing innovative therapies. The focus is on combating inflammation, infections, and cancer. The company's business model is to guide compounds through the stages of clinical development and then license or sell them to large pharmaceutical companies. The different divisions of Innovation Pharmaceuticals are diverse and encompass dermatology, oncology, and infectious diseases, among others. The company has a pipeline of products currently in clinical trials or nearing entry into the clinical phase. One of Innovation Pharmaceuticals' leading products is Brilacidin, a synthetic peptide that can be used as a broad-spectrum antibiotic as well as a potential drug for the treatment of inflammation and cancer. Brilacidin has shown promising results in clinical studies and is currently being investigated in various indications. Another promising product of Innovation Pharmaceuticals is Kevetrin, a drug used for the treatment of cancer. Kevetrin is unique as it focuses on the p53 tumor suppression mechanism. Kevetrin is currently in the clinical phase of development, and Innovation Pharmaceuticals has begun to explore its use in various types of cancer. Innovation Pharmaceuticals also has an extensive portfolio of compounds and technologies in the preclinical stage. These compounds have the potential to create new therapeutic options for various diseases, including autoimmune diseases, chronic inflammatory diseases, and infectious diseases. In summary, Innovation Pharmaceuticals Inc. is a leading biopharmaceutical company focusing on the development of innovative therapeutics in various areas of medicine. The company has an impressive pipeline of products and technologies at various stages of development that have shown promising results. Innovation Pharmaceuticals has the potential to significantly improve the lives of patients with rare and severe diseases by developing novel therapies that are currently unavailable. Innovation Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Innovation Pharmaceuticals's Shares Outstanding

Innovation Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Innovation Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Innovation Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Innovation Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Innovation Pharmaceuticals stock

How many stocks are there of Innovation Pharmaceuticals?

The current number of stocks of Innovation Pharmaceuticals is 505.77 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Innovation Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Innovation Pharmaceuticals evolved in recent years?

The number of shares of Innovation Pharmaceuticals has increased by 0.38% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Innovation Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Innovation Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Innovation Pharmaceuticals pay?

Over the past 12 months, Innovation Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Innovation Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Innovation Pharmaceuticals?

The current dividend yield of Innovation Pharmaceuticals is .

When does Innovation Pharmaceuticals pay dividends?

Innovation Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Innovation Pharmaceuticals?

Innovation Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Innovation Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Innovation Pharmaceuticals located?

Innovation Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Innovation Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Innovation Pharmaceuticals from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Innovation Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Innovation Pharmaceuticals in the year 2023?

In the year 2023, Innovation Pharmaceuticals distributed 0 USD as dividends.

In which currency does Innovation Pharmaceuticals pay out the dividend?

The dividends of Innovation Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Innovation Pharmaceuticals

Our stock analysis for Innovation Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innovation Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.